Pliant Therapeutics公司宣布，其研发药物Pln-101095针对免疫检查点抑制剂（ICI）难治性实体瘤患者的一期临床试验最新数据，将在2026年美国癌症研究协会（AACR）年会上进行专题报告。这项突破性研究旨在评估Pln-101095在晚期实体瘤患者中的安全性与初步疗效，为肿瘤免疫治疗领域提供新的潜在方向。
Pliant Therapeutics公司宣布，其研发药物Pln-101095针对免疫检查点抑制剂（ICI）难治性实体瘤患者的一期临床试验最新数据，将在2026年美国癌症研究协会（AACR）年会上进行专题报告。这项突破性研究旨在评估Pln-101095在晚期实体瘤患者中的安全性与初步疗效，为肿瘤免疫治疗领域提供新的潜在方向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.